May 15, 2020
The Federal Circuit will continue to hold remote oral arguments into the summer, Gilead is allowing some generic-drug makers to produce versions of its antiviral treatment remdesivir, and companies that are allegedly upcharging for coronavirus-related products are continuing to find themselves in court for trademark law violations.